FPP29 |
Catalog No.GC81461
One-Click Copy Product Info
|
FPP29 is a potent peptide-based FOXM1 PROTAC degrader.
Products are for research use only. Not for human use. We do not sell to patients.
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
In Vivo, FPP29 (7.5-15 mg/kg; intratumoral injection) inhibits hepatocellular carcinoma tumor growth in xenograft mice by downregulating FOXM1[1].
In Vitro, FPP29 (24 h) potently inhibits the viability of HCCLM3 cells, with an IC50 of 3.65 μM after 24 h of incubation[1]. FPP29 (4 μM; 24-48 h) significantly inhibits the migration ability of HCCLM3 cells[1]. FPP29 (2-8 μM; 24 h) induces dose-dependent apoptosis in HCCLM3 cells following 24 h of incubation at concentrations of 2 μM, 4 μM, and 8 μM[1]. FPP29 (2-8 μM; 6-48 h) downregulates the protein expression of FOXM1, cyclin B1 and CDC25B in HCCLM3 cells, and regulates epithelial-mesenchymal transition markers in a dose-dependent and time-dependent manner (upregulating E-cadherin and downregulating N-cadherin)[1].
References:
[1]. Jia S, et al. A novel designed fully peptide-based PROTAC, FPP29, demonstrates its potent cytotoxic effects to liver cancer HCCLM3 cells by targeting FOXM1. Bioorg Chem. 2025;163:108626.
| Cas No. | SDF | ||
| Formula | C145H228N56O32 | M.Wt | 3267.72 |
| Solubility | DMSO: 25 mg/mL (7.65 mM; Need ultrasonic) | Storage | Sealed storage, away from moisture |
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 306 μL | 1.5301 mL | 3.0602 mL |
| 5 mM | 61.2 μL | 306 μL | 612 μL |
| 10 mM | 30.6 μL | 153 μL | 306 μL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)